Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Medtronic
Teva
Boehringer Ingelheim
Fuji
US Army
Healthtrust
Express Scripts
Dow

Generated: June 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022433

« Back to Dashboard

NDA 022433 describes BRILINTA, which is a drug marketed by Astrazeneca Pharms and is included in one NDA. It is available from two suppliers. There are six patents protecting this drug and two Paragraph IV challenges. Additional details are available on the BRILINTA profile page.

The generic ingredient in BRILINTA is ticagrelor. There are twenty-one drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ticagrelor profile page.
Summary for 022433
Tradename:BRILINTA
Applicant:Astrazeneca Pharms
Ingredient:ticagrelor
Patents:6
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 022433
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BRILINTA ticagrelor TABLET;ORAL 022433 NDA AstraZeneca Pharmaceuticals LP 0186-0776 N 0186-0776-60
BRILINTA ticagrelor TABLET;ORAL 022433 NDA AstraZeneca Pharmaceuticals LP 0186-0776 N 0186-0776-94

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength90MG
Approval Date:Jul 20, 2011TE:RLD:Yes
Regulatory Exclusivity Expiration:Sep 3, 2018
Regulatory Exclusivity Use:EXTENDS THE 2011 APPROVAL OF BRILINTA FOR USE BEGINNING WITH ACS TO USE BEGINNING MORE REMOTE FROM MYOCARDIAL INFARCTION
Patent:➤ Try a Free TrialPatent Expiration:Jul 15, 2018Product Flag?Substance Flag?YDelist Request?
Patent:➤ Try a Free TrialPatent Expiration:Dec 2, 2019Product Flag?YSubstance Flag?YDelist Request?Y
Patented Use:REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Colorcon
McKinsey
McKesson
Queensland Health
Johnson and Johnson
Boehringer Ingelheim
Daiichi Sankyo
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.